Synaptic Pharmaceutical Corporation

American Home Products Corporation

Wyeth

H. Lundbeck A/s

Synaptic Pharmaceutical Coorporation

Jonathan A Bard

Richard L Weinshank

Theresa A Branchek

Carlos C Forray

Beth E Borowsky

Kelli E Smith

Mary W Walker

Christophe P G Gerald

Kenneth A Jones

Jack Steven Jacobsen

Eileen Marie Kajkowski

Heidi Sofia

Bradley A Ozenberger

Stephen G Walker

David S Howland

Mark L Stahl

William Stuart Somers

Rajiv Chopra

Tatos Akopian

Kristine Svenson

Bethany Annis Freeman

This invention is directed to the three dimensional crystal structure of Beta-site APP Cleaving Enzyme (BACE), and to the use of this structure in rational drug design methods to identify agents that may interact with active sites of BACE. Such agents may represent new therapeutics in the treatment and/or prevention of Alzheimer's Disease.

Method for identifying agents that interact with beta-site APP cleaving enzyme (BACE)

Novel proteins which bind human &#x3b2;-amyloid peptide, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided. Transgenic animals and knockout animals are also provided.

&#x3b2;-amyloid peptide-binding proteins and polynucleotides encoding the same

This invention provides an isolated nucleic acid encoding a mammalian galanin receptor, an isolated galanin receptor protein, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor, nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining binding of compounds to mammalian galanin receptors.

Method of using cells expressing galanin receptor 3 (GALR3)

Novel proteins which bind human &#x3b2;-amyloid peptide, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided.

This invention provides an isolated nucleic acid molecule encoding a human Y4 receptor, an isolated protein which is a human Y4 receptor, vectors comprising an isolated nucleic acid molecule encoding a human Y4 receptor, mammalian cells comprising such vectors, antibodies directed to the human Y4 receptor, nucleic acid probes useful for detecting nucleic acid encoding human Y4 receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human Y4 receptor, pharmaceutical compounds related to human Y4 receptors, and nonhuman transgenic animals which express DNA encoding a normal or a mutant human Y4 receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatment involving the human Y4 receptor.

Method of obtaining compositions comprising Y4 specific compounds

Novel proteins which bind human &bgr;-amyloid peptide, polynucleotides which encode these proteins, and methods for producing these proteins are provided. Diagnostic, therapeutic, and screening methods employing the polynucleotides and polypeptides of the present invention are also provided. Transgenic animals and knockout animals are also provided.

&bgr;-amyloid peptide-binding proteins and polynucleotides encoding the same

This invention provides an isolated nucleic acid, vectors, transformed mammalian cells and non-human transgenic animals that encode and express normal or mutant alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention also provides a protein, and an antibody directed to the protein and pharmaceutical compounds related to alpha 1a, alpha 1b and alpha 1c adrenergic receptors. This invention provides nucleic acid probes, and antisense oligonucleotides complementary to alpha 1a, alpha 1b and alpha 1c adrenergic receptor genes. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human alpha 1a, alpha 1b and alpha 1c adrenergic receptors.

DNA encoding human alpha 1 adrenergic receptors and uses thereof

This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT receptor and an isolated nucleic acid molecule encoding a human 5-HT receptor, an isolated protein which is a mammalian 5-HT receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT receptor, pharmaceutical compounds related to the human 5-HT receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with a human 5-HT receptor.

Method of obtaining compositions

This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT receptor and an isolated nucleic acid molecule encoding a human 5-HT receptor, an isolated protein which is a mammalian 5-HT receptor, an isolated protein which is a human 5-HT receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT receptor, pharmaceutical compounds related to the human 5-HT receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human 5-HT receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with a human 5-HT receptor.

DNA encoding a human serotonin receptor (5-HT4B) and uses thereof

Process for determining the agonist or antagonist of galanin receptor (GALR3)

DNA encoding galanin GALR3 receptors and uses thereof

This invention provides an isolated nucleic acid molecule encoding a mammalian 5-HT,receptor and an isolated nucleic acid molecule encoding a human 5-HT,receptor, an isolated protein which is mammalian 5-HT,receptor, vectors comprising an isolated nucleic acid molecule encoding a mammalian 5-HT,receptor, vectors comprising an isolated nucleic acid molecule encoding a human 5-HT,receptor, mammalian cells comprising such vectors, antibodies directed to the 5-HT,receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian or human 5-HT,receptor, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian or human 5-HT,receptor, pharmaceutical compounds related to the human 5-HT,receptor. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with a human 5-HT,receptor.

This invention provides an isolated nucleic acid encoding a mammalian LPA receptor, a purified mammalian LPA receptor, vectors comprising isolated nucleic acid encoding an mammalian LPA receptor, cells comprising such vectors, antibodies directed to a mammalian LPA receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian LPA receptor, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding mammalian LPA receptor, transgenic, nonhuman animals which express DNA encoding a normal or a mutant mammalian LPA receptor, methods of isolating an mammalian LPA receptor, methods of treating an abnormality that is linked to the activity of the mammalian LPA receptor, as well as methods of determining binding of compounds to mammalian LPA receptors.

Growing community of inventors

Doylestown, PA, United States of America

Jonathan A Bard